Phase 3 Colorectal Clinical Trials
83 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 83 trials
Recruiting
Phase 2Phase 3
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
Colorectal (Colon or Rectal) Cancer
RemeGen Co., Ltd.80 enrolled19 locationsNCT07462143
Recruiting
Phase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Metastatic Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Unresectable Colorectal Carcinoma+1 more
ECOG-ACRIN Cancer Research Group408 enrolled60 locationsNCT05863195
Recruiting
Phase 3
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
Colorectal, Cancer
Canadian Cancer Trials Group834 enrolled20 locationsNCT07152821
Recruiting
Phase 3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled235 locationsNCT06662786
Recruiting
Phase 3
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Stage IV Colorectal Cancer AJCC v8Metastatic Colorectal Adenocarcinoma
Alliance for Clinical Trials in Oncology364 enrolled183 locationsNCT05673148
Recruiting
Phase 3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled241 locationsNCT06750094
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
CRC (Colorectal Cancer)
Incyte Corporation700 enrolled273 locationsNCT07284849
Recruiting
Phase 3
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Metastatic Colorectal Cancer
EMD Serono Research & Development Institute, Inc.1,020 enrolled3 locationsNCT07549412
Recruiting
Phase 2Phase 3
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb990 enrolled279 locationsNCT07221357
Recruiting
Phase 3
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer (CRC)
Summit Therapeutics600 enrolled76 locationsNCT07228832
Recruiting
Phase 2Phase 3
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
Gastric CancersColorectal, CancerPancreatic Ductal Adenocarcinoma+1 more
GE Healthcare175 enrolled2 locationsNCT07219238
Recruiting
Phase 3
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
Colorectal Neoplasms
Merck Sharp & Dohme LLC100 enrolled32 locationsNCT05239741
Recruiting
Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
Amgen450 enrolled286 locationsNCT06252649
Recruiting
Phase 3
FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients
Advanced Colorectal Cancer
University Hospital, Antwerp150 enrolled9 locationsNCT07558083
Recruiting
Phase 3
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
MSI-H/dMMR Colorectal CancerResectable Colon Cancer
Akeso386 enrolled1 locationNCT07412613
Recruiting
Phase 3
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Colorectal NeoplasmsNeoplasms by SiteGastrointestinal Neoplasms+7 more
Pfizer800 enrolled156 locationsNCT07222800
Recruiting
Phase 3
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD190 enrolled63 locationsNCT05652894
Recruiting
Phase 2Phase 3
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Colorectal, CancerLiver Metastases
Sun Yat-sen University156 enrolled1 locationNCT06280495
Recruiting
Phase 2Phase 3
Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management
Open Colorectal SurgeryAppendectomyPostoperative Pain+5 more
Dr. Asma Abdus Salam263 enrolled1 locationNCT06996561
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled382 locationsNCT05253651